CCR investigators have already begun using the nCounter Analysis System in various studies related to the mechanisms involved in cancer development. These include investigations into the role of inflammation in cancer and RNA-interference or gene-knockdown experiments, and studies measuring changes in gene expression in response to drug treatment. These studies are expected to lead to a better understanding of the disease and ultimately to more targeted treatment options.

The nCounter Analysis System is well suited to cancer research because it is highly sensitive, has a very small sample requirement, and can handle multiple sample types including whole blood and degraded samples, said Wayne Burns, Acting Chief Executive Officer of NanoString Technologies. We are proud to be part of the portfolio of technologies offered to scientists at this prestigious institute and look forward to supporting NCI researchers in their mission to discover new insights about this complex disease.

The nCounter Analysis System is comprised of a fully automated sample prep station, a digital analyzer, the CodeSet (molecular barcodes) and all other reagents needed to perform the analysis. Custom and off-the-shelf assay panels are available for gene expression analysis, with additional applications such as miRNA profiling and copy number variation detection currently in development.

Source: NanoString Technologies, Inc.